Cargando…
Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study
Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce. Methods: Publications rel...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252465/ https://www.ncbi.nlm.nih.gov/pubmed/35795565 http://dx.doi.org/10.3389/fphar.2022.921385 |
_version_ | 1784740271175499776 |
---|---|
author | Qi, Xiangjun Li, Yanlong Liu, Wei Wang, Yifan Chen, Zhuangzhong Lin, Lizhu |
author_facet | Qi, Xiangjun Li, Yanlong Liu, Wei Wang, Yifan Chen, Zhuangzhong Lin, Lizhu |
author_sort | Qi, Xiangjun |
collection | PubMed |
description | Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce. Methods: Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and R package Bibliometrix. Results: A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the Journal of Clinical Oncology. A total of 37 burst references and five burst references were identified between 2017–2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns. Conclusion: This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns. |
format | Online Article Text |
id | pubmed-9252465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92524652022-07-05 Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study Qi, Xiangjun Li, Yanlong Liu, Wei Wang, Yifan Chen, Zhuangzhong Lin, Lizhu Front Pharmacol Pharmacology Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce. Methods: Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and R package Bibliometrix. Results: A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the Journal of Clinical Oncology. A total of 37 burst references and five burst references were identified between 2017–2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns. Conclusion: This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns. Frontiers Media S.A. 2022-06-20 /pmc/articles/PMC9252465/ /pubmed/35795565 http://dx.doi.org/10.3389/fphar.2022.921385 Text en Copyright © 2022 Qi, Li, Liu, Wang, Chen and Lin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Qi, Xiangjun Li, Yanlong Liu, Wei Wang, Yifan Chen, Zhuangzhong Lin, Lizhu Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study |
title | Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study |
title_full | Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study |
title_fullStr | Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study |
title_full_unstemmed | Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study |
title_short | Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study |
title_sort | research trend of publications concerning antibody-drug conjugate in solid cancer: a bibliometric study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252465/ https://www.ncbi.nlm.nih.gov/pubmed/35795565 http://dx.doi.org/10.3389/fphar.2022.921385 |
work_keys_str_mv | AT qixiangjun researchtrendofpublicationsconcerningantibodydrugconjugateinsolidcancerabibliometricstudy AT liyanlong researchtrendofpublicationsconcerningantibodydrugconjugateinsolidcancerabibliometricstudy AT liuwei researchtrendofpublicationsconcerningantibodydrugconjugateinsolidcancerabibliometricstudy AT wangyifan researchtrendofpublicationsconcerningantibodydrugconjugateinsolidcancerabibliometricstudy AT chenzhuangzhong researchtrendofpublicationsconcerningantibodydrugconjugateinsolidcancerabibliometricstudy AT linlizhu researchtrendofpublicationsconcerningantibodydrugconjugateinsolidcancerabibliometricstudy |